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Abstract: Glioblastoma (GBM) is the most frequent and aggressive primary brain tumor and is associ-
ated with a poor prognosis. Despite the use of combined treatment approaches, recurrence is almost
inevitable and survival longer than 14 or 15 months after diagnosis is low. It is therefore necessary to
identify new therapeutic targets to fight GBM progression and recurrence. Some publications have
pointed out the role of glioma stem cells (GSCs) as the origin of GBM. These cells, with characteristics
of neural stem cells (NSC) present in physiological neurogenic niches, have been proposed as being
responsible for the high resistance of GBM to current treatments such as temozolomide (TMZ).
The protein Kinase C (PKC) family members play an essential role in transducing signals related
with cell cycle entrance, differentiation and apoptosis in NSC and participate in distinct signaling
cascades that determine NSC and GSC dynamics. Thus, PKC could be a suitable druggable target
to treat recurrent GBM. Clinical trials have tested the efficacy of PKCβ inhibitors, and preclinical
studies have focused on other PKC isozymes. Here, we discuss the idea that other PKC isozymes
may also be involved in GBM progression and that the development of a new generation of effective
drugs should consider the balance between the activation of different PKC subtypes.
Keywords: glioblastoma; protein kinase C; glioma stem cells; neurogenesis; neural stem cells;
temozolomide; enzastaurin; epidermal growth factor receptor; neuregulin
1. Gliomas: Characteristics, Classification and Epidemiology
Gliomas account for 30% of all tumors of the central nervous system (CNS) and 80%
of all malignant brain tumors in adults [1]. Although diffuse gliomas are considered as rare
disorders, approximately 100,000 people worldwide are diagnosed with this pathology
every year, with it being the second most common cancer in children and adolescents
(26% of all cancers) [2–4]. Glioma incidence varies with age, sex, ethnicity, tumor histology,
and between populations around the world [5].
Based on histopathological criteria and malignancy grade, gliomas are classified as as-
trocytomas and oligodendrogliomas (OD), either diffuse (grade II) or anaplastic (grade III)
and glioblastomas (GBM; grade IV). Briefly, histological features used in the clinical diagno-
sis of gliomas include: nuclear atypia (grade III), in addition to necrosis and microvascular
changes (grade IV). In addition, these latter tumors exhibit high infiltrative and prolifera-
tive capacity and increased mitotic activity compared to grade II lesions [6]. This review
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focuses on GBMs as they are the most common (54% of all gliomas) and the most aggres-
sive in adults, with a median overall survival (OS) of ≈15 months. Additionally, GBM has a
high incidence of recurrency (>90%), despite intensive clinical management including surgery,
radiotherapy and adjuvant chemotherapy. GBM can appear at any age but the peak incidence
is between 75 to 84 years [7]. The incidence of these tumors is approximately 50% higher in
males compared to females [8] and it differs substantially between ethnic groups, e.g., it is
higher in Caucasians as compared to black populations [7,9,10]. As regards their location,
they are most commonly situated in the supratentorial region (frontal, parietal, temporal and
occipital lobes), with the highest incidence in the frontal lobe [11], while they are rarely located
in the cerebellum [12]. Furthermore, the incidence of GBM increases in patients with hereditary
tumor syndromes, such as Turcot syndrome [13] and Li-Fraumeni syndrome [14].
Since diagnosis and prognosis of gliomas based on histological features is insufficient,
the 2016 World Health Organization Classification of Tumors of the Central Nervous Sys-
tem (2016 CNS WHO) incorporated molecular parameters to improve clinical interventions
in patients with this pathology [15]. Amongst the molecular genetic alterations used to
redefine glioma entities, the most common are mutations in the isocitrate dehydrogenase
1 and 2 (IDH1, IDH2) genes and the 1 p/19q co-deletion status [16–18]. According to
the IDH condition, gliomas are divided into IDH-mutant (IDH1 R132 or IDH2 R172) and
IDH-wild-type; 90% of GBMs (usually primary or “de novo” GBMs) are wild-type for
IDH and have a poor prognosis (median OS of 1.2 years). Meanwhile, secondary GBM
(10%) develops through progression from a low-grade lesion and is associated with a better
prognosis and survival rate due to the IDH mutation (median OS of 3.6 years) [1,6,19–21].
This biomarker, used in combination with the loss of heterozygosity in chromosomal arms
1p/19q for the diagnosis of grade II and III oligodendrogliomas, is linked to favorable
clinical behaviors [20,21]. In the case of tumors which cannot be classified into any of
these groups due to lacking sufficient pathological and genetic information (i.e., absence
of appropriate diagnostic molecular testing or inconclusive results), the 2016 CNS WHO
assigned the NOS (Not Otherwise Specified) category, which should be the subject to future
studies [15,16]. Nonetheless, other biomarkers with predictive value of the progression
and response to the first-front therapeutics are also frequently used in the clinic. The loss of
ATRX (alpha thalassemia/mental retardation syndrome X-linked) is a recurrent marker of
astrocytoma and secondary GBM and is associated with IDH and TP53 mutations, which
are linked to a good outcome [22]. Hypermethylation of the MGMT (O6-methylguanine-
DNA methyltransferase) promoter is considered an important predictor of a good response
to chemotherapy with temozolomide (TMZ) in glioma patients [23,24]. Telomerase re-
verse transcriptase (TERT) promoter mutations have been detected in more than 50% of
primary adult GBM and are correlated with increased telomerase activity [24,25], having
been linked to lower survival times in GBM patients [26]. However, in combination with
IDH1 and MGMT mutations, these mutations are good predictors of grade II and grade III
gliomas [27]. Finally, EGFR (epidermal growth factor receptor) expression, without loss of
PTEN (phosphatase and tensin homolog), explains the sensitivity of gliomas to tyrosine
kinase inhibitors [28]. In conclusion, the use of molecular traits is assisting with the classifi-
cation of gliomas, the high biological heterogeneity of which require the use of different
experimental models for their study [29] and different strategies of clinical management.
2. Neurogenesis and Glioblastoma
Over recent years the concept of neurogenesis has evolved, from being considered
a process constrained to embryonic stages, to now being considered relevant in adult-
hood [30]. Neurogenesis is defined as the process in which neural stem cells (NSCs) are
activated and form new cells of a neural phenotype. NSCs can form neural progenitor
cells (NPCs) that have a faster capacity of division as compared to NSCs. NPCs also
have the potential to generate all the brain cell lineages, including neurons, astrocytes
and oligodendrocytes [31–33]. Indeed, stem cell dynamics are determined by several
signals that promote symmetric or asymmetric divisions, for either the maintenance of
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the stem cell pool or promotion of cellular differentiation. In further detail, symmetric
auto-regenerative divisions expand the NSC population by generating two cells identical
to the mother cell, whereas symmetric differentiated division generates two daughter
cells that are different from the mother cell [34]. Asymmetric divisions render two cells,
one identical to the mother cell and another more differentiated one. Neurogenesis occurs
in different regions of the adult brain under physiological conditions, primarily—and also
the most extensively explored—subventricular zone (SVZ) and the dentate gyrus (DG) of
the hippocampus [35,36]. As opposed to mouse models, adult neurogenesis in the human
DG is still a controversial issue. Some authors uphold that there is a continuous addition
of new neurons in the DG [37], others support the idea that neurogenesis does not really
occur in the adult human hippocampus [38–40]. In any case, ageing decreases the number
of proliferating cells in the human SVZ [38]. The SVZ is located in the lateral walls of the
brain ventricles and it is characterized by a specific architecture with a spatial arrangement
of the neuroepithelium similar to the embryonic stage [41–43]. However, NSCs of the
embryonic stage can continuously change their potentiality, in contrast to the adult state
where NSC potentiality is relatively stable [41]. The NSCs of the SVZ (also called B1 type
cells) have many characteristics that are typical of astrocytes [36,44] but have the capacity to
generate all neural cell lineages including neurons, astrocytes and oligodendrocytes. Quies-
cent B1 cells can be activated and change their state to finally generate cells with a different
grade of differentiation [36,45]. Via asymmetric division, these B1 cells can form C type cells
(transit-amplifying cells) that have the capacity to form type A cells (neuroblasts) [36,44,46].
In humans, neuroblasts originating from the SVZ migrate to the striatum and not to the OB
(olfactory bulb) as is the case in mice [47]. Both the persistence of B1 cells in the adult SVZ and
their capacity to either be in quiescent or activated state, suggest that these cells may be the
possible origin of malignant gliomas [48,49]. Furthermore, gliomas contain glioma stem cells
(GSC) with characteristics that are similar to type B1 cells and have been postulated as the cells
responsible for the origin of GBM and for the resistance of some malignant tumors to medical
treatments. Different signaling pathways support or misfit the dynamics of the niche, which
can be altered by the presence of mutations in the signaling molecule genes and receptors or
by environmental factors that regulate their presence within the niche [50] (Figure 1).
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with the development of GBM. In the SVZ, NSCs are located close to the blood vessels, 
which in turn, are essential for their maintenance and survival [54–56]. In cancer, vascu-
larization is essential for understanding tumor growth and metastasis, and therefore, it 
has a direct relationship with malignancy. This is of special interest, as GBM is one of the 
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ture. All these connections establish a specific niche that contributes to creating a micro-
environment that promotes proliferation [60–62]. In addition, it is important to highlight 
that the human SVZ can be separated into four layers, the ependymal layer (I), the hypo-
cellular layer (II), the astrocytic ribbon layer (III) and the transitional layer (IV); between 
the ependymal layer and the neurogenic astrocytes, there exists a hypocellular gap [63–
65] that is related with proliferation of NSC. Within the SVZ niches, the oxygen concen-
tration can determine cell survival and stemness in NSC and GSC [66,67]. In GBM, hy-
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3. The SVZ Cytoarchitecture as an Important Niche to Induce Glioblastoma
As indicated above, the SVZ is located on the lateral border of the lateral ventricles
and it constitutes one of the neurogenic niches that is preserved in adulthood. Around
50–60% of GBMs, which are associated with a short life expectancy, are linked to mu-
tations in the cells of the SVZ, pointing to an association between both [51,52]. In fact,
GBMs associated with the SVZ are most likely to be multifocal at diagnosis, recur at great
distances from the initial lesion/s, and exhibit a transformation from NSC to GSC [53].
Not only the characteristic neuroepithelium tissue is responsible for the proliferation and
differentiation capacity of this brain region, but the vascular architecture is also intimately
related with the development of GBM. In the SVZ, NSCs are located close to the blood
vessels, which in turn, are essential for their maintenance and survival [54–56]. In cancer,
vascularization is essential for understanding tumor growth and metastasis, and therefore,
it has a direct relationship with malignancy. This is of special interest, as GBM is one
of the most malignant and vascularized types of brain tumor [57]. Indeed, GSCs inter-
act with the vasculature, and specifically, with pericytes within the niche [58,59] and are
able to transdifferentiate into endothelial cells (EC) in order to contribute to their own
vasculature. All these connections establish a specific niche that contributes to creating
a microenvironment that promotes proliferation [60–62]. In addition, it is important to
highlight that the human SVZ can be separated into four layers, the ependymal layer (I),
the hypocellular layer (II), the astrocytic ribbon layer (III) and the transitional layer (IV);
between the ependymal layer and the neurogenic astrocytes, there exists a hypocellular
gap [63–65] that is related with proliferation of NSC. Within the SVZ niches, the oxygen
concentration can determine cell survival and stemness in NSC and GSC [66,67]. In GBM,
hypoxia favors GSC self-renewal and it also induces the secretion of several factors, such as
TGFβ, that promotes angiogenesis via vascular endothelial growth factor (VEGF) or stroma
cell-derived factor 1 (SDF-1) [68,69].
4. Glioma Stem Cells and Neural Stem Cells
In addition to NSCs, GSCs have been isolated and cultivated in vitro. Their charac-
terization has revealed similarities between both types of cells, including self-renewal,
proliferation capacity and differentiation. One of the most important points that they have
in common is the expression of several markers, such as nestin [70] (Figure 1). This interme-
diate filament protein is characteristic of stem cells and progenitor cells, and is expressed
during embryonic development and in adult undifferentiated cells [31]. Additionally,
expression of nestin in tumor cells is correlated with the malignancy of the tumor [71]
and with the cell capacity to form spherical aggregates, commonly called neurospheres or,
more precisely, tumorospheres or oncospheres [72]. Neurosphere assays have been crucial
in finding similarities between NSC and GSC properties [73–75], such as the capability to
be passaged several times and to be cultured under differentiation conditions. Moreover,
GSCs that are capable of forming tumorospheres allow in vivo studies of tumorigenesis as
they are able to initiate a new tumor in xenotransplanted nude mice [74].
Another shared marker between both types of stem cells is CD133, also called pro-
minin. CD133 is a membrane bound glycoprotein with a crucial function in cell differenti-
ation, proliferation and in epithelial to mesenchymal transition [76]. Most CD133+ cells
have the capacity to form tumorospheres and are present in a small subpopulation of cells
in brain tumors [77]. This marker is also related to the clonal capacity of these kind of cells.
Lastly, CD133+ cells have a high level of telomerase activity that is correlated with neural
stem cell abilities [78,79]. Despite this, the use of CD133 as a marker of tumorigenesis
has been recently challenged because of the discovery of differentiated cells expressing
CD133 and the capacity to initiate tumors in some CD133- cells [76,80].
Other molecular markers are involved in molecular pathways that determine prolifer-
ation, differentiation or migration, such as the EGFR, which can be amplified to form up to
10 additional copies in GBM [76,81]. Other markers present in GSC are CD15, characteristic
of the embryonic stage and also present in NSC [82,83], L1CAM which is critical to the
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adhesion process in growth and migration in CNS development and also in the survival of
CD133+ GSCs [84], and several transcriptional factors (e.g., Sox2, Olig2, Nanog, c-Myc) that
can be used in the identification of GSCs and are important for their survival [85] (Figure 1).
Although NSCs and GSCs share multiple similarities, there are also crucial differences
that are based on the capacity of invasion and the immune response characteristics of GSC,
that are not present in NSCs [86], and are key in glioma research. The use and identification
of appropriate markers forms the basis to clarify the similarities and differences between
GSC and NSC in the research of new therapeutic targets that could help the development
of effective treatments.
5. Active Signaling Pathways Involved in Proliferation, Tumor Growth and Invasion
in GBM
The study of GBM-related pathways is critical in developing new therapeutic drugs.
The tyrosine kinase pathways involve the tyrosin kinase receptors (RTKs). RTKs are recep-
tors for several ligands, such as hormones, growth factors, and cytokines, that initiate either
the Ras small GTPase/mitogen activated kinase (Ras/ERK) or the Ras/Phosphoinositide
3-kinase-Akt (Ras/PI3K-Akt) pathways, both related to proliferation and survival but also
to differentiation [87]. The aforementioned EGFR is among the most relevant RTKs and
is involved in proliferation, related to the high resistance to treatments [24,88,89]. Other
relevant RTKs include VEGFR, tightly linked with angiogenesis and hypoxia [90]; fibroblast
growth factor receptor (FGFR), which plays a role in tumorigenesis and is used to increase
proliferation in vitro [91,92]; platelet-derived growth factor receptor(PDGFR); hepatocyte
growth factor receptor/mesenchymal-epithelial transition factor (HGFR/c-MET), involved
in the development of several types of cancer including GBM [93,94]. As a control mecha-
nism of these pathways, PTEN functions as a tumor suppressor by negatively regulating
protein kinase signaling cascades which are implicated in tumorigenesis. Due to its dual
phosphatase activity, PTEN inhibits the PI3K/AKT/mTOR pathway by dephosphorylating
either phosphatidylinositol or the downstream phosphorylated substrates of this pathway.
Loss of PTEN is frequent in GBM [95], in which the activity of the PI3K-AKT pathway
increases proliferation and facilitates migration. However, PTEN-deficient GBM depend
differently on the two PI3K isoforms, p110a and p110b for proliferation and migration,
respectively [96].
Protein kinase C (PKC) is key in understanding the cell proliferation, differentiation,
survival and migration processes mediated by these pathways in the normal brain and also
in pathogenic conditions [97], as we will discuss in the following sections.
6. Protein Kinase C: Characteristics, Structure, Classification and Activating Molecules
The PKC family includes serine-threonine kinases that catalyze the phosphoryla-
tion of a huge variety of substrates which are important in several biological processes,
such as cell cycle entry, apoptosis, proliferation, and differentiation, among other basic
functions [98–100]. Under normal conditions, PKC activation requires the binding of regu-
lators, such as diacylglycerol (DAG), calcium and phosphatidyl serine (PS). Depending
on their regulatory domains and their basic activators, 10 different PKC isozymes have
been described that are classified in three subfamilies [101]: classical, novel and atypical
PKCs (See Figure 2). Classical PKCs (α, β, and γ) use calcium, DAG and PS for their
activation, while novel PKCs (δ, ε, θ, and η) are also activated by DAG and PS but are
calcium independent. Atypical PKCs (λ/J and ζ) are regulated by protein–protein interac-
tions [102]. All PKCs contain a C-terminal kinase domain and an N-terminal regulatory
domain. The N-terminal regulatory domain of both classical and novel PKCs contains a
C1 domain that is divided into C1A and C1B subdomains and a C2 domain. In the case of
classical PKC, the C2 domain and C1 domain are adjacent and bind Ca2+ and DAG, respec-
tively. In contrast, the C2 domain of novel PKC does not respond to Ca2+, therefore, these
enzymes are DAG-sensitive and Ca2+-independent [101,103–106]. Atypical PKCs lack the
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C2 domain but contain a C1 domain, which does not respond to DAG. Atypical PKCs
contain a PB1 domain that binds PB1 binding proteins, which have scaffolding functions.
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As indicated above, the physiological molecule that activates classical and novel PKC
in cells is DAG that, once synthesized in a reaction catalyzed by phospholipase C, binds to
the C1 domain of classical and novel PKC. Chemical compounds with molecular structures
similar to DAG have been widely used as PKC activating molecules in research. The best
known is phorbol myristate acetate (PMA), which irreversibly activates PKC, translocating
it to the plasma membrane, but also mediates its ubiquitination and degradation, as we
will explain below. PMA has been described as tumorigenic in most tissues [107], although
the mechanism underlying such tumorigenic effect is still a matter of debate.
Other PKC activating compounds have been described with a chemical structure
similar to that of PMA. This is the case of prostratin, a diterpene with a 12-deoxyphorbol
structure isolated from the Samoan plant Homolantus nutans. Prostratin has been described
as a non-tumor promoting compound with the capability to activate classical and novel
PKC, without showing carcinogenic properties [108]. Similar phorbol derived diterpenes
with a tigliane or lathyrane skeleton have been described with similar PKC activating
properties that also promote NSC proliferation [109,110]. Additionally, semi-synthetic
prostratin-like epoxytiglianes have proven to be efficacious against established tumors
in mice [111]. Thus, a great variety of compounds that are able to target specific PKC
isozymes are now available.
PKC activation has been proven to be crucial for NSC proliferation and differentia-
tion, although not all isoenzymes behave identically during these processes [97]. For ex-
ample, the proliferation of NSCs isolated from the SVZ of induced adult mice is stim-
ulated with classical PKC activating diterpenes with a 12-deoxyphorbols or lathyrane
structure [109,110,112]. This facilitates the ADAM17-mediated release of EGFR ligands
such as TGFα [113] and activates the PI3K-AKT and MAPK pathways [114], in addition
to also activating cyclin D1 expression [109]. On the contrary, PKC inhibition facilitates
the differentiation of NSCs towards a neuronal phenotype, reducing their proliferation
rate [115].
In contrast, specific activation of novel PKCs with diterpenes with a lathyrane struc-
ture, such as EOF2, promotes differentiation towards a neuronal phenotype, reducing
proliferation by facilitating the ADAM17-mediated release of neuregulin. The selectiv-
ity of ADAM17 for EGFR ligands, or for neuregulins, depends on the phosphorylation
reactions that take place in the cytosolic domain of the membrane-bound pro-TGFα or
pro-neuregulin molecules. These reactions are catalyzed by kinases of the PKC family [116].
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In particular, activating PKCα by PMA results in the phosphorylation of TGFα, amphireg-
ulin and Heparin binding EGF-like growth factor (HB-EGF) membrane-bound pro-ligands
enabling their shedding mediated by ADAM17 and releasing the soluble domain of the
growth factor to the extracellular space [116]. On the contrary, activation of the novel PKCδ
enables ADAM17-mediated NRG1 ectodomain shedding. The scission of the ectodomain is
enabled by the phosphorylation of serine 286 in the intracellular domain of NRG1, which is
catalyzed by PKCδ [98,117]. Taken together, this evidence indicates that ADAM17 substrate
specificity and selectivity depends on the activation of different PKC isozymes in order to
exert its crucial role on the secretion of different neurotrophic factors [116,117] which are
necessary for governing NSC physiology.
7. Protein Kinase C and Glioblastoma
In contrast to the usual actions of PKCs in different cancer cell types, their role in
the development of GBM seems to be different depending on the isozyme [118]. Below,
we analyze the different PKC isozymes to understand their implication in the development
of GBM and their potential as targets for GBM treatments. Figure 3 contains a summary of
the activities of different PKC isozymes in GBM physiology.
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7.1. PKCα
Several studies have shown that PKCα plays a l i ll s rvival and prolifera-
tion, as well as in promoting invasion. Inhibiting PKCα activity may result in GBM, along
with reductions in cell growth, survival, migration and invasion. Thus, PKCα seems to have
a specific function in glioma for ation because it is required for the activation of several
pathways. For example, PKCα links the EGFR and mTORC1 pathways, independent of the
AKT pathway [119], which participates in glioma viability. This suggests that inhibition of
PKCαmay lead to a reduction in the viability of glioma cells. More recently, a decrease in
GBM cell proliferation and induced apoptosis caused by the cooperative inhibition of Janus
kinase 2 (JAK2) and PKCα has been demonstrated [120]. Moreover, the basic fibroblast
growth factor (bFGF) is one of the principal mitogens in glioma development, which is
linked to the ERK1/2 signaling pathway, activated by PKCα [121]. PKCα is indirectly
related to migration and invasion, specifically because of its role in the ADAM10 mediated
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release of the adhesion molecule, N-cadherin. PKCα inhibitors seem to significantly reduce
GBM cell migration [122]. Another pathway involved in GBM growth is the LPA1-induced
translocation of PKCα to the cell nucleus, as blocking this pathway leads to a reduction
in cell proliferation in GBM [123]. All these reports suggest a role for classical PKCα in
GBM tumorigenesis, indicating that the regulation of PKCα activity can be targeted as a
potential treatment of GBM.
7.2. PKCβ
This PKC isozyme seems to have opposite roles in GBM. It has long been considered to
play a role in the induction of angiogenesis, facilitating tumor progression. Thus, targeting
PKCβ in GBM treatment has been long pursued in preclinical and clinical studies. Consid-
ering that angiogenesis is essential for GBM development, PKCβmay play a direct role in
tumor establishment and progression because of its role as a key molecule in vessels forma-
tion [124]. The most promising therapeutic approach using PKCβ as a target molecule came
from the use of a specific inhibitor called enzastaurin (LY317615), that directly affected the
proliferation capacity of cells. Specifically, this inhibitor suppressed the AKT signaling
pathway, inducing tumoral cell death and suppressing tumor growth and angiogenesis at
the same time [125]. Despite these promising results, phase III clinical studies in recurrent
GBM have not demonstrated a better efficiency of enzastaurin in comparison with other ex-
isting pharmacological agents, such as lomustine, an extensively used oral treatment [126].
On the contrary, a report from Liu et al. assigned an indirect role for PKCβ II activation as
an inhibitor of GBM tumor growth, as it prolongs survival of a mouse orthotopic xenografts
model and induction of apoptosis through inhibition of YAP/TAZ proteins of the hippo
pathway [127,128]. Thus, two opposite roles for PKCβ have been described: a direct role
on angiogenesis and tumor progression; an indirect role in detaining tumor growth and
increasing survival.
7.3. PKCδ
PKCδ has been reported to play a key role in several cellular functions within tu-
mors, such as proliferation and survival. Chen et al. demonstrated that PKCδ depletion
prevents sphere outgrowth from tumor cell cultures as well as the tumor development
in xenograft models [129]. Other studies have reported that the reduction in PKCδ af-
fects glioma invasiveness through its relationship with the regulation of the extracellular
matrix components; indeed, the interference of PKCδ expression reduced the release or
extracellular levels of the protein tenascin-C, resulting in the downregulation of matrix
metalloprotease MMP-12, a metalloprotease required for cell migration and involved in
tumor invasion [130]. Additional studies have discovered a role of PKCδ in increases in
glioma-initiating cell populations, and in the reduction in cellular sensitivity to cancer treat-
ments [131]. In addition, activation of PKCδ in glioma cells activates glycerol-3-phosphate
dehydrogenase (GPDH), an essential enzyme in several glioma cell functions due to its
basic functions in glycolysis, respiration and phospholipid biosynthesis. Additionally,
phosphorylation of GPDH at threonine 10 correlates with the levels of p-PKCδ in human
GBM and with the local number of macrophages within the zone releasing IL-1β, which
negatively affects tumor grade and patient survival [132], depicting a role for PKCδ in
GBM growth and progression.
7.4. PKCε
Novel PKCε has been related with several cell processes including cell survival and
apoptosis. In GBM, PKCε is overexpressed in cell cultures [133]. Glioma cells treated
with TRAIL (TNF-related apoptosis-inducing ligand), while also subjected to silencing
PKCε expression, undergo apoptosis, suggesting that this kinase is required for GSC
survival [134]. Other authors have emphasized that the loss of PKCε contributes to the
downregulation of genes related to autophagy pathways in GBM cells [135]. In addition,
PKCε activates ERK, specifically at focal adhesions, in order to mediate integrin-dependent
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glioma cell adhesion and motility [136,137]. This plays a role in the regulation of the
recycling of endocytosed integrin-β1 to facilitate its return to the plasma membrane [138].
7.5. PKCη
Novel PKCη plays important roles in cell proliferation, differentiation and cell
death [139–141]. Using glioma-derived cell lines, AKT and mTOR were identified as
the downstream targets of PKCη in GBM [142]. Conversely, other authors propose that
PKCη induces GBM cell proliferation via ERK and ERK1 phosphorylation, involving
MEK/mitogen activation [143]. Additionally, PKCη has been related to the resistance to
UV and gamma radiation by blocking the apoptotic cascade via caspase-9 activation [144].
7.6. PKCλ/ι
Atypical PKCλ/ι is also involved in regulating the biology of GBM cells, particularly in
terms of survival and cell migration. PKCλ depletion produces an increase in RhoB activity,
inhibiting cell motility and invasion in GBM cells [145]. In addition, PKCλ promotes GBM
cell survival by regulating the pro-apoptotic protein, Bad, via the PI3-kinase pathway [146].
A recent study, in which atypical PKCι and PKCζ inhibitors (ICA and ζStat, respectively)
were tested in combination with TMZ in vitro in the U87MG cell line, showed an induction
of apoptosis and a reduction in cell migration. However, the use of these inhibitors in mice
transplanted with U87MG cells did not show a higher reduction in tumor volume in mice
treated with ICA vs. TMZ [147].
7.7. PKCζ
The atypical PKCζ has been proposed as a tumor suppressor because its depletion
increases tumorigenesis in several types of cancers including GBM [148]. Additionally,
PKCζ is postulated as a potential downstream effector of fatty acid-mediated alterations in
GBM growth and migration [149]. Indeed, some authors associate PKCζwith migration:
silencing of PKCζ impairs the phosphorylation of LIN-11, IsI1 and MEC-3 protein domain
kinase (LIMK), which is important for actin polymerization, affecting migration and in-
vasion in GBM [150]. Additionally, PKCζ is related to NF-κB function in the signaling
pathways dependent on MMP-9, a key metallopeptidase in tumor invasion [151]. A recent
study demonstrated that inhibitors of this kinase, combined with TMZ, notably reduced
the cell viability of GBM-derived cell lines [147].
8. General Concerns on Conventional and Targeted Therapies in Glioblastoma
The standard treatment of newly diagnosed GBs follows the Stupp protocol, that con-
sists of the maximal surgical resection of the tumor, accompanied by a regimen of ra-
diotherapy and temozolomide (TMZ) administration, aimed at the unspecific damage of
the DNA in highly proliferative cells as a means to trigger their death. TMZ acts as an
adjuvant alkylating agent of the ionized radiation by methylating the DNA, which most
often occurs at the N-7 and O-6 positions of guanine residues, and N-3 positions of alanine
residues [152]. Inclusion of TMZ leads to an increase in the OS by 2.5 months and reducing
the mortality rate by 37% [153]. However, >90% of the cases relapse with gliomas that
are more aggressive and resistant to this treatment. Second-line treatment chemotherapy
mainly consists of nitrosourea-based DNA alkylating agents such as CCNU (lomustine),
BCNU (carmustine), ACNU (nimustine), or fotemustine, the type II topoisomerase inhibitor
mitoxantrone and the monoclonal antibody against VEGF bevacizumab. Overall, follow-
ups of patient cohorts have reported a significant increase in OS and progression-free
survival (PFS) of these patients over the last 10 years but these intensive efforts are still far
for a complete cure.
In light of the different driver mutations found in GBM, several trials have aimed at
developing targeted therapies directed against specific RTKs, such as EGFR, PDGFR, FGFR or
VDGFR and their associated signaling pathways [154]. However, although some of them
have provided interesting results, most clinical trials have not gone beyond phase III [155].
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Intra-Tumor Heterogeneity and Tumor Microenvironment: Two Obstacles for Targeted Therapies
One of the factors mediating resistance to conventional and targeted therapies is the
intra-tumor heterogeneity and plasticity of GBM. GBM harbors different cell types with
somatic mutations that may confer different sensitivity to treatments. Therefore, resistance
to therapy is not homogeneous within the tumor and depends on the molecular signatures
of specific cells [156]. It is most likely that current therapeutic approaches only eliminate
the sensitive tumor cell fraction, whereas the other cell sub-populations remain intact and
result in relapse [155].
The tumor microenvironment influences this tumor evolutionary process and con-
tributes to intra-tumor heterogeneity. Non-GSCs within the tumor, such as tumor-associated
macrophages and microglial cells, contribute to generating this microenvironment. These
immune cells—that account for almost 50% of the tumor mass—secrete factors that create
a continuously evolving environment, together with hypoxia and availability of nutrients.
Thus, interactions between cancer cells and the fluctuating tumor microenvironment mod-
ifies epigenetic regulation and gene expression, affecting its heterogeneity and constant
evolution [156].
Identifying the key drivers of alterations in genes and their expression across different
cell types is crucial in the development of therapeutic approaches that modify intra-tumor
evolution and change drug resistance patterns for successful therapies.
9. Clinical Trials Using PKC Targeting Drugs
Several clinical trials conducted over the past 20 years have tested the effects of PKC
inhibitors in GBM, mainly classical PKC inhibitors in the treatment of recurrent GBM.
Treatment of relapsing patients is still challenging, as current clinical management involves
surgery, radiotherapy and TMZ treatment with no better outcomes having been found by
using alternative drugs (reviewed in Finch et al., 2021 [156]).
The first clinical trials using PKC targeting drugs tested the efficacy of tamoxifen.
This nonsteroidal agent with high lipid solubility is able to cross the blood–brain barrier
(BBB) and reach the tumor. Tamoxifen elicits the association of PKC to the membrane,
followed by an irreversible activation, and subsequent down-regulation of the enzyme,
leading to cell growth inhibition [157], cellular apoptosis, and at high doses, chemore-
sistance reversion [158,159]. For the treatment of GBM, Couldwell and colleagues and
Brandes and colleagues were the first to use high-doses of tamoxifen to inhibit PKC, based
on in vitro assays that evaluated apoptosis in GBM cells either alone, or in combination
with procarbazine in phase II clinical trials. The most relevant finding was an increase
in radiosensitivity [160,161]. However, the OS rates shown in these studies were 6.8 and
7.2 months, and the time to progression was 3.3 months. More promising results were
observed in a more recent study in which tamoxifen was tested in combination with
TMZ. In this study the observed median time to progression was 9.5 months and the OS
was 17.5 months [162]. Additional clinical trials have tested tamoxifen in combination
with other agents such as procarbazine or TMZ to affect PKC functionality and other
targets [163–165] (see Table 1 for further details).
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Table 1. Summary of protein kinase C-related clinical trials for the treatment of glioblastoma.
Target Authors and Year Trial Phase Nº Patients Dose PFS OS
Tamoxifen PKC Couldwell et al 1996 [160] Phase II trial 32
200 mg/day (100 mg twice daily) of tamoxifen was
administered to males 160 mg/day (80 mg twice daily) of
tamoxifen was administered to females
n.d. 7.2 months
Tamoxifen +
Procarbazine PKC + DNA Brandes et al 1999 [164] Phase II trial 53
100 mg/day of tamoxifen + 100 mg/m2/day of
procarbazine were administered for 30 days with 30-day
intervals between cycles
3 months (median) 6.2 months
Tamoxifen + TMZ PKC + DNA Spence et al. 2004 [165],Cristofori et al. 2013 [162] Phase II trial 16
40 mg twice daily of tamoxifen for 1 week and was
escalated to 60 mg, 80 mg then 100 mg + 75 mg/m2/day
of TMZ for 6 weeks, repeated every 10 weeks, with a
maximum of 5 cycles
n.d. 6 months
PKC + DNA Cristofori et al. 2013 [162] Phase II trial 32 80 mg/m
2/day of tamoxifen + 75–150 mg/m2/day of




Radiation PKC Robins et al. 2006 [161] Phase II trial 75
80 mg/m2/day of tamoxifen, divided in 4 doses of
20 mg/m2 every 6 h, was administered during and after
of 60 Gy in 30 fractions × 2 Gy of radiotherapy
2.9 months
(median) 11.3 months
Enzastaurin PKCβ Kreisl et al. 2009 [166]Kreisl et al. 2010 [167]
Phase I trialPhase
I/II trial
2215 (Phase I) 103
(Phase II)
800 mg/day of enzastaurin and 400 mg twice daily and
500 mg/day and 250 mg twice daily for patients not
taking EIAEDs and 1000 mg/day and 500 mg twice daily
for patients taking EIAEDs in phase I, patients who were
taking EIAEDs, received 525, 700 and 900 mg/day of
enzastaurin and patients in phase II, who were not taking










DNA/Stathmin-4 Wick et al. 2010 [126] Phase III trial 266
500 mg/day of enzastaurin vs. 100 to 130 mg/m2 of














TMZ PKC β + DNA Rampling et al. 2012 [168] Phase I trial 28
250 mg/day (once daily); 500 mg/day (once daily);







PKC β + DNA Butowski et al. 2010 [169] Phase I trial 12
Radiation therapy 1.8–2.0 Gy × 30 fractions 5 days a




Bevazizumab PKC β + VEGF Odia et al. 2016 [170] Phase II trial 40
Enzastaurin 500 or 875 mg/day + bevacizumab
10 mg/kg intravenously biweekly 2.0 months 7.5 months
Aprinocarsen PKC α Grossman et al. 2005 [171] Phase II trial 21 2 mg/kg/day of aprinocarsen was administered for21 days per month
1.2 months
(median) 3.4 months
PFS, progression-free survival; OS, overall survival; EIAEDs: enzyme-inducing anti-epileptic drugs; Gy: gray; n.d: not determined; OS: overall survival; PFS: progression-free survival; PKC: protein kinase C;
TMZ: temozolomide.
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Undoubtedly, the most relevant clinical trials implicating PKC in GBM so far have
analyzed the effects of enzastaurine. This small molecule is an inhibitor of PKC β that has
been used for the treatment of a variety of tumors and, similarly to tamoxifen, is a lipid
soluble compound that can cross the BBB. Enzastaurin was originally developed as an
anti-angiogenic agent based on the role of PKC β in angiogenesis [125,172–174]. However,
its specificity is not very high for PKC β since, at higher concentrations, the drug can
inhibit other PKC isoforms including PKCα [172,173]. Despite this, enzastaurin has shown
a longer half-life than TMZ (12–40 h vs. 1.8 h) and remarkable radiographic response
rates in recurrent high-grade gliomas [168,169]. Although a phase III clinical trial failed to
demonstrate such efficacy after comparing the monotherapies of enzastaurin and lomustine
in recurrent GBM, the PFS was 1.5 months and OS was 6.6 months [126]. Therefore, these
trials did not improve the effectiveness of current treatments, even in combination with
lomustine, a nitrosourea that interacts with DNA, commonly used as a chemoterapeutic
agent [126,166,167]. Other strategies have been explored—such as a combination with
bevacizumab—with no further improvement [170]. Therefore, clinical trials using the PKC
inhibitor enzastaurin have not succeeded at limiting GBM progression and invasion, either
alone, or in combination with TMZ or other compounds. In addition to tamoxifen and
enzastaurin, a trial to test the PKCα inhibitor aprinocarsen has been carried out without
success [171].
As stated above, the tumor microenvironment and intra-tumor heterogeneity should
be considered as responsible for the lack of improvement found in phase III trials with
enzastaurin. Alteration of PKC expression and activity among the different cell types
within the tumor needs also to be considered. Alternatively, enzastaurin itself might
modify PKC expression or alter the signaling cascades that interact with PKC activity,
creating resistance. Thus, identification of signaling cascades associated with PKC and
compounds that target these molecules might help in the design of additional therapies
that overcome intra-tumor heterogeneity and TME induced evolution.
10. A Connection between GBM Tumorigenesis, EGFR Signaling and PKC Isozymes
RTKs have long been targeted in the treatment of GBM [175]. As explained above,
PKCs are intimately related with the EGFR signaling pathway which is responsible for
the proliferation and survival of GBM. This receptor is an RTK that belongs to the ErbB
family of receptors (EGFR, Her2, ErbB3 and ErbB4) [176]. EGFR can be activated by
numerous ligands such as EGF, TGFα, heparin-binding EGF-like growth factor (HB-EGF),
amphiregulin and epiregulin. Stimulation of the EGFR dependent signaling pathways,
PI3K-AKT and mTOR, MAPK-Erk, or JAK/STAT, transduces signals into the nucleus,
leading to gene expression changes that are responsible for tumor proliferation, genetic
immortality, invasion, angiogenesis, and the avoidance of immune surveillance [177].
ErbB3 and ErbB4 bind neuregulins are activating signaling pathways with antiproliferative
and differentiating effects. One of the most common mutations in GBM is the appearance
of EGFRvIII via deletion of exons 2 to 7, that leads to a constitutively active EGFR that is
not regulated by endocytosis [178].
Another molecule of interest in GBM treatment is PI3K. Due to the effect of PTEN loss
in GBM growth, survival and migration, PI3K inhibitors have been used in clinical trials
but have yielded little success [179,180]. The failure of these inhibitors may be related to
their specificity to inhibit only one of the two PI3K isoforms (p110a or p110b).
It is now known that specific PKC isozymes participate in the release of specific ErbB
ligands: phosphorylation of the membrane-bound pro-ligands facilitates their ectodomain
shedding in a reaction catalyzed by ADAM17. Thus, classical PKC isozymes promote the
release of EGFR and Her2 ligands, whereas novel PKC isozymes promote the release of
ErbB4 ligands neuregulins [116,117,181]. Therefore, PKCs not only regulate intracellular
signaling cascades initiated by the EGFR receptor, but as a main function, they also regulate
the initiation of these signaling pathways. Taking these facts into consideration, it seems
reasonable to hypothesize that regulating the activity of specific PKC isozymes (i.e., ac-
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tivating the novel PKC isozymes and inhibiting the classical variants) may result in an
interesting strategy to halt GBM growth and survival, migration and invasion.
11. Future Perspectives
PKC enzymes have been reported to play a complex role in GBM development and
prognosis. As shown in this review, the different isozymes participate in growth, survival,
and invasiveness of GBM. Additionally, they are involved in initiating EGFR ligand release,
which is one of the main signaling pathway leading to GBM proliferation, migration
and invasiveness (see Figure 4). Thus, inhibiting classical PKC isozymes may result in
a reduction in GBM proliferation and tumor progression because of the inhibition of
the EGFR pathway. Although preclinical studies indicate that the specific activation of
PKC enzymes may result in adequate cancer treatments, the use of the PKCβ inhibitor
enzastaurin in clinical trials did not show a better efficacy than current GBM treatment
drugs. Except for the recent study by Cullen et al. [111], in which a library of putative PKC
activating compounds were tested for the treatment of melanoma, most of the classical
PKC activators used so far in cancer studies promote the sustained irreversible enzyme
activation and degradation and lack specificity for individual isozymes such as PMA. It has
recently been proposed that, in order to target PKC for cancer treatment, therapies should
better focus on the induction or re-establishment of specific PKC activities rather than on
the inhibition of these enzymes.
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of epidermal growth factor eceptor (EGFR) by ligands released in an ADAM17-mediated manner
stimulate intracellular pathways leading to cell proliferation, cell cycle entrance and GBM growth.
The use of enzastaurin inhibits these pathways. In addition to this drug, activation of novel PKC
isozymes may facilitate the ADAM17-mediated release of neuregulins, stimulating differentiation
and inhibiting proliferation survival and growth.
For this purpose, we require drug screenings to reveal novel molecules that specifically
activate each isozyme in a reversible manner, without causing the down-regulation or
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degradation of their ligand. We propose in Figure 4 that the selective activation of different
PKC isozymes may lead to the release of different growth factors, which will differentially
activate ErbB receptors to modulate different cell functions. Thus, the activation of classical
PKC may lead to EGFR ligand release and—as a consequence—to the activation of EGFR-
dependent proliferation and the survival of GBM. Conversely, the activation of novel PKC
may lead to the release of ADAM17-dependent neuregulins, impairing EGFR ligand release
and slowing down GBM proliferation and growth. We hypothesize that the combination of
these PKC targeting drugs with current treatments may enhance prognosis and survival
time. Diterpenes with the capacity to individually regulate classical and novel PKC
have recently been described for use in neuronal regeneration [113,114] and as putative
treatments for other cancer types [111]. Thus, these agents could prove useful in the
development of drugs either in standalone or in combined strategies with other compounds
(e.g., PI3K inhibitors).
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ACNU Nimustine
ASCL1 Achaete-scute complex homolog-1
ATRX Alpha thalassemia/mental retardation syndrome X-linked
BBB Blood–brain barrier
BCNU Carmustine
bFGF Basic fibroblast growth factor
CCNU Lomustine
CD133 Prominin1
CNS WHO World Health Organization Classification of Tumors of the Central Nervous System






EGFR Epidermal growth factor receptor
FGFR Fibroblast growth factor receptor
GBM Glioblastomas
GD3 GD3 ganglioside
GFAP Glial fibrillary acidic protein
GLAST Astrocytic glutamate transporter
GPDH Glycerol-3-phosphate dehydrogenase
GSC Glioma stem cells
HB-EGF EGF-like growth factor
HGFR/c-MET Hepatocyte growth factor receptor/mesenchymal–epithelial transition factor
IDH 1, IDH2 Isocitrate dehydrogenase 1 and 2
JAK2 Janus kinase 2
LIMK MEC-3 protein domain kinase
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MAG Myelin associated glycoprotein
MAP2 Microtubule associated protein 2
MBP Myelin basic protein
MGMT O6-methylguanine-DNA methyltransferase
NeuN Hexaribonucleotide Binding Protein-3
NG2 Neuron-glial antigen 2
NOS Not Otherwise Specified
NPCs Neural progenitor cells
NSCs Neural stem cells
O4 Surface antigen O4
OB Olfactory bulb
OS Overall survival
PDGFR Platelet-derived growth factor receptor
PDGFRa Platelet derived growth factor receptor alpha
PFS Progression-free survival
PKC Protein kinase C
PMA Phorbol myristate acetate
PS Phosphatidyl serine
PSA-NCAM Polysyalated-neural cell adhesion molecule
PTEN Phosphatase and tensin homolog
RTKs Tyrosin kinase receptors
SOX2 Sex determining region Y-box 2
SVZ Subventricular zone
TERT Telomerase reverse transcriptase
TME Tumor microenvironment
TMZ Temozolomide
TRAIL TNF-related apoptosis-inducing ligand
Tuj1 Neuron-specific class III beta-tubulin
VEGFR Vascular endothelial growth factor receptor
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